FULC241220C1000
- 3.00
- 0.000.00%
Fulcrum Therapeutics Newsroom
Fulcrum Therapeutics (NASDAQ:FULC) Shareholders Have Endured a 77% Loss From Investing in the Stock Three Years Ago
Subdued Growth No Barrier To Fulcrum Therapeutics, Inc. (NASDAQ:FULC) With Shares Advancing 32%
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
Fulcrum Therapeutics to Participate in Upcoming December Conferences
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Fulcrum Therapeutics Slides As Insider Purchases Lose Another US$362k
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $14
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Fulcrum Therapeutics Analyst Ratings
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript Summary
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
Fulcrum Therapeutics | 10-Q: Q3 2024 Earnings Report
Fulcrum Therapeutics Reports Q3 EPS (35c), Consensus (41c)
Express News | Fulcrum Therapeutics Inc: Cash Runway Into at Least 2027
Express News | Fulcrum Therapeutics Q3 Operating Income USD -25.126 Million
Express News | Fulcrum Therapeutics Q3 Net Income USD -21.696 Million
Earnings Scheduled For November 13, 2024
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
Fulcrum Therapeutics's Earnings Outlook